ScoreComparison
Why is Nektar Therapeutics ?
1
Poor long term growth as Net Sales has grown by an annual rate of -18.43% and Operating profit at 10.61% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
- NET PROFIT(HY) At USD -71.61 MM has Grown at -70.13%
- NET SALES(Q) At USD 10.86 MM has Fallen at -21.34%
- OPERATING CASH FLOW(Y) Lowest at USD -203.76 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 608.25%, its profits have fallen by -49.8%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -1.01% over the previous quarter and currently hold 2.46% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Nektar Therapeutics for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Nektar Therapeutics
608.25%
1.29
183.33%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-18.43%
EBIT Growth (5y)
10.61%
EBIT to Interest (avg)
-7.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.04
Sales to Capital Employed (avg)
0.49
Tax Ratio
0.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.81%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.35
EV to EBIT
-14.11
EV to EBITDA
-14.22
EV to Capital Employed
-25.54
EV to Sales
33.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-172.26%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
NET PROFIT(HY)
Higher at USD -71.61 MM
ROCE(HY)
Highest at -53.6%
RAW MATERIAL COST(Y)
Fallen by -2.82% (YoY
-19What is not working for the Company
NET PROFIT(HY)
At USD -71.61 MM has Grown at -70.13%
NET SALES(Q)
At USD 10.86 MM has Fallen at -21.34%
OPERATING CASH FLOW(Y)
Lowest at USD -203.76 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 20.94 times
Here's what is working for Nektar Therapeutics
Net Profit
Higher at USD -71.61 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -2.82% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Nektar Therapeutics
Net Profit
At USD -71.61 MM has Grown at -70.13%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Net Sales
At USD 10.86 MM has Fallen at -21.34%
over average net sales of the previous four periods of USD 13.81 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -203.76 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debtors Turnover Ratio
Lowest at 20.94 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
